The GiveWell Blog

All Malaria Charity Posts

Podcast Episode 29: Behind the Analysis — Assessing Past Malaria Nets Grants

(updated on: ) | by GiveWell Staff

GiveWell’s research doesn’t end once we’ve made a grant. We evaluate a subset of completed grants, comparing what we thought would happen to what actually took place, then try to use what we learn to improve our future funding decisions. Over the past year, we’ve formalized and expanded this work, publishing comprehensive “lookbacks” for select grants.

A recent lookback on grants GiveWell made to fund insecticide-treated net distributions supported by the Against Malaria Foundation (AMF) in the Democratic Republic of Congo (DRC) illustrates the growing capacity of GiveWell’s research team. We drew on multiple independent data sources, funded qualitative interviews to gather more information, and conducted a novel empirical analysis to deepen our confidence.

In this episode, based on a conversation originally aired on GiveWell’s internal podcast for staff*, GiveWell’s co-founder and CEO Elie Hassenfeld provides additional context while GiveWell’s Chief Research and Program Officer Teryn Mattox dives deep into the details with Program Director Alex Cohen and Researcher Steven Brownstone, examining how we conducted the lookback, what we found, and how what we learned may shape our future nets grantmaking.

Read More

GiveWell Opens RFI for Malaria Pilots and Research

| by GiveWell Staff

GiveWell is launching a new request for information (RFI) to expand and strengthen our malaria grantmaking in Africa and help our donors make a greater impact. Expressions of interest can be submitted through one of two tracks, the first for malaria chemoprevention and vector control pilot programs and the second for research and evaluation. Submissions are due June 24.

Malaria kills around 600,000 people annually, mostly children under five in Africa. To date, GiveWell has directed more than $1 billion in donations to malaria prevention programs. As our research capacity grows, this RFI aims to pilot promising malaria prevention strategies and generate evidence to address a range of questions in malaria prevention and epidemiology.

We’d like to reach as many organizations as possible—please share with your network and consider applying!

Read More

More than a Spoonful of Medicine

| by GiveWell Staff

What does it take to prevent malaria? Some of the programs GiveWell recommends might sound straightforward—for example, seasonal malaria chemoprevention (SMC) programs provide antimalarial drugs to young children—but the process of accomplishing this is not simple at all.

Below, we offer a post from Malaria Consortium that describes the many complex steps required to carry out an SMC campaign. See our reports for more information about the evidence for SMC and about Malaria Consortium’s SMC program.

Read More

Why GiveWell funded the rollout of the malaria vaccine

| by Audrey Cooper

Since our founding in 2007, GiveWell has directed over $600 million to programs that aim to prevent malaria, a mosquito-borne disease that causes severe illness and death. Malaria is preventable and curable, yet it killed over 600,000 people in 2021—mostly young children in Africa.

Following the World Health Organization’s approval of the RTS,S/AS01 malaria vaccine (RTS,S) in late 2021, GiveWell directed $5 million to PATH to accelerate the roll out of the vaccine in certain areas of Ghana, Kenya, and Malawi. This grant aimed to enable these communities to gain access to the vaccine about a year earlier than they otherwise would, protecting hundreds of thousands of children from malaria.

Although we’re very excited about the potential of the RTS,S malaria vaccine to save lives, it isn’t a panacea. We still plan to support a range of malaria control interventions, including vaccines, nets, and antimalarial medicine.

In this post, we will:

  • Explain how we found the opportunity to fund the malaria vaccine
  • Discuss why we funded this grant
  • Share our plan for malaria funding moving forward

Read More

IPTi for malaria: a promising intervention with likely room to scale

| by Miranda Kaplan

Intermittent preventive treatment in infants (IPTi) for malaria provides preventive antimalarial medicine to children under 12 months old. It is among the most promising programs we’ve identified in our active pipeline of new interventions. It’s also underutilized, and the population it targets is especially vulnerable to malaria. That implies potential to open up large amounts of room for more funding if IPTi begins to be used more widely—our crude estimate is between $50 million and $200 million globally once it’s scaled—which is something we’re increasingly thinking about as we aim to direct $1 billion in cost-effective funding by 2025. In September 2021, we recommended a small grant to Malaria Consortium and PATH to assess the feasibility and cost-effectiveness of implementing IPTi at national scale in two countries. We’re hopeful that this scoping exercise will answer some of our many open questions about IPTi, and that this intervention continues to look promising as we learn more.

Read More

Initial thoughts on malaria vaccine approval

(updated on: ) | by Julie Faller

The World Health Organization (WHO) recently recommended the widespread use of the malaria vaccine RTS,S/AS01 for children. It provides an additional, effective tool to fight malaria. This is great news!

We’ve been following this vaccine’s development for years and, in the last few months, have been speaking with organizations involved in its development and potential wider rollout.

Our work on RTS,S (and other malaria vaccines) is ongoing, and we might significantly update our views in the near future. But because we’ve been following its progress, we’re sharing some initial thoughts.

Read More

Next Page »